Balanced product information
Evidence, limitations and safety — in one consistent format.
This page separates authorised uses from investigational or reported uses. It does not provide personal medical advice or dosing instructions.
Product name
CagriSema (cagrilintide with semaglutide)
Catalogue label details describe what is displayed; they do not independently verify composition, quality, batch release or UK marketing authorisation.
What is it?
CagriSema is the development name for a combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist.
Clinical-trial formulations and schedules are tightly controlled. The separate 4mg plus 4mg pen presentation shown in this catalogue should not be assumed to match a trial product.
Intended / recognised uses
Authorised / recognised uses
- There is no UK-authorised medical use for the CagriSema combination. Semaglutide has authorised uses only in separate, named medicinal products.
Reported / investigational uses
- The combination is being investigated for chronic weight management and type 2 diabetes in clinical trials.
- Research endpoints and company announcements are not marketing authorisation or individual treatment advice.
How it works
Semaglutide activates GLP-1 receptors involved in glucose control, gastric emptying, appetite and satiety.
Cagrilintide mimics amylin signalling associated with satiety and food intake. The clinical balance of the combined actions remains under study.
Potential benefits / effects
- Trials have reported weight and glucose-related effects in selected participants.
- No benefit is established for the exact HELIX presentation, and trial results cannot be used to promise individual outcomes.
Potential benefit is not a guarantee of benefit for any individual.
Risks & warnings
- The combination's long-term safety and rare adverse effects are not fully established.
- Potential concerns include marked gastrointestinal effects, dehydration, gallbladder disease, pancreatitis and low blood glucose when combined with some diabetes medicines.
- Unverified compounded or retail presentations add quality, concentration, sterility and storage risks.
Possible side effects
Commonly reported in component or combination trials
- Nausea, diarrhoea, constipation, vomiting and reduced appetite.
- The frequency for the exact product displayed here is not established.
Serious or urgent concerns
- Persistent severe abdominal pain, severe dehydration, serious allergy, gallbladder symptoms or significant hypoglycaemia require urgent assessment.
- Unexpected or severe symptoms should be reported promptly in a research setting.
Who should not use it / precautions
- It should not be used outside an authorised clinical trial or other lawful specialist route.
- Pregnancy, breastfeeding, childhood, previous pancreatitis, severe gastrointestinal disease, diabetic eye disease, kidney disease and gallbladder disease require particular caution.
- People taking diabetes medicines need professional review.
Interactions
- Combination-specific interaction data remain limited.
- Insulin or sulfonylureas may increase hypoglycaemia risk.
- Effects on gastric emptying may alter absorption of oral medicines; all medicines should be reviewed by a clinician or pharmacist.
Regulatory / legal status
- CagriSema is investigational and has no UK marketing authorisation.
- Authorisation of semaglutide in other named products does not authorise cagrilintide, the combination, or this catalogue presentation.
Monitoring / professional supervision
- Clinical studies use eligibility screening and protocol-led monitoring of weight, glucose control, hydration, gastrointestinal effects and safety laboratory measures.
- Symptoms suggesting pancreatitis, gallbladder disease, hypoglycaemia or significant dehydration require prompt assessment.
- There is no validated self-use monitoring plan for this catalogue product.
Evidence & sources
Sources are selected for regulatory status, recognised uses and material safety information. They do not validate the HELIX-labelled presentation.
- ClinicalTrials.gov — CagriSema trial NCT06267092
- Novo Nordisk — CagriSema development update
- MHRA — GLP-1 medicines: what you need to know
- MHRA — Strengthened pancreatitis warnings for GLP-1 medicines
Sources accessed and content reviewed 12 September 2026. Regulatory status can change; consult the current official record.
Information disclaimer
HELIX — FOR INFORMATION ONLY. NOT FOR SALE.
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
For a UK-facing website, this disclaimer does not by itself establish legal compliance. Public advertising of prescription-only medicines and advertising of unlicensed medicines are subject to legal restrictions; the catalogue, wording and presentation require appropriate regulatory review.
Licensed-provider information
Where permitted by applicable law, HELIX may display contact details for independent third-party providers whose registration details have been checked against an appropriate official register. Visitors may contact a listed provider directly to enquire about lawful availability and eligibility requirements.
Any supply is subject to the provider’s assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
Registration status can change. Review the provider's regulator, registration number, official-register record and last-checked date, then verify the current status independently before engaging.